Spotlight Stories

  1. Heading Back Home To The Heart 11/1/2023

    Cardior Pharmaceuticals, led by CEO and cofounder Claudia Ulbrich, is developing what may be a much broader approach to heart failure, one that seeks to restore the diseased heart to its natural healthy state.

  2. Life Biosciences Grows Up: A Q&A With Jerry McLaughlin 10/2/2023

    Through the boom and bust of anti-aging buzz cycles, Life Biosciences has continued its focus on epigenetic reprogramming with an increasingly focused pipeline and development strategy.

  3. Using AI To Find And Develop Safer Medicines 10/2/2023

    Montai Health CEO Margo Georgiadis is using what she’s learned at McKinsey, Discover, Google, Mattel, and Ancestry to reinvent drug discovery and development, with a focus on long-term safety.

  4. Rescuing A Company's Core Purpose 10/2/2023

    When Dr. Scott Braunstein moved from his position as chairman of the board and interim CEO to become permanent CEO of Marinus Pharmaceuticals in August 2019, he had already concluded an overbroad focus was holding the company back.

  5. To America, A New Biopharma Model 9/1/2023

    Ketan Mehta, founder and CEO of Tris Pharma. Mehta came to the U.S. in the late 1970s. Since then, he has built a career in pharma and, more recently, an entirely new company with a triad of businesses — platform technology licensing, generic medicines, and new drug development.

  6. Taking A Fresh Approach To Finance At BMS 9/1/2023

    A rising star in BMS’s finance department, Tatiana Simonelli, SVP, finance commercialization at BMS discusses her path to senior leadership, and how talent diversity can boost business results.

  7. Biotech Veteran Pushes New Science And Regulatory Change 9/1/2023

    Ashvattha Therapeutics CEO Jeff Cleland hopes to bring hydroxyl dendrimer therapeutics to market for the first time, while also pushing for policy and regulatory change as an advocate for BIO.

  8. Vincerx Pharma: Finding Strength In Symbiosis 8/1/2023

    Ahmed Hamdy and Raquel Izumi are putting the lessons, hard knocks, and experiential wisdom they have gained over a decade in biotech to work at Vincerx.

  9. Going European — Affimed's American CBO 8/1/2023

    Taking the CBO position at Affimed offered Denise Mueller a way to apply her skills in an international biotech startup environment, where she could help shape the company’s innovative approach to cancer immunotherapy.

  10. Novo Nordisk Returns To Growth, With Growing Pains 8/1/2023

    Novo Nordisk’s return to growth is largely due to an explosion of demand for its anti-obesity products. However, challenges with supply and insurance coverage persist.